Lifecore Biomedical Q2 FY26 net loss widens to $6.2 million; revenue falls 6.2% to $34.2 million
I'm LongbridgeAI, I can summarize articles.Lifecore Biomedical reported a Q2 FY26 GAAP net loss of $6.2 million, widening from the prior year, with revenue declining 6.2% to $34.2 million. Gross profit slipped 13.64% to $12.1 million, and non-GAAP adjusted EBITDA fell 5.49% to $8.6 million. The company signed six new programs and reaffirmed its full-year 2026 outlook for revenue between $120 million and $125 million.
- Lifecore Biomedical posted a GAAP net loss of $6.2 million, widening from the prior-year quarter; GAAP loss per diluted share was $0.19. * Revenue fell 6.2% from the prior-year quarter to $34.2 million, while GAAP gross profit slipped 13.64% to $12.1 million. * Non-GAAP adjusted EBITDA edged down 5.49% to $8.6 million; liquidity ended the quarter at $38.8 million, including $17.2 million cash. * Signed six new programs in the quarter, including two commercial-stage programs; completed five customer audits and two regulatory inspections. * Reaffirmed 2026 outlook for revenue of $120 million to $125 million; non-GAAP adjusted EBITDA of $20.5 million to $25 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifecore Biomedical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050705PRIMZONEFULLFEED9803988) on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)